Test furmonertinib for advanced EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to consent to the study
- Have advanced non-squamous non-small cell lung cancer that cannot be cured with surgery or radiation
- Have an EGFR 19Del or L858R mutation confirmed by a ctDNA blood test (from an approved hospital)
- Have not had prior treatment for advanced lung cancer (except certain limited early treatments before 6 months)
- Have at least one measurable tumor spot on scans and be well enough for treatment (ECOG 0–1)
- Be able and willing to take oral study medicine and provide blood samples for genetic testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
This trial tests whether a combination of two drugs, RC108 and Furmonertinib, can help people with non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutation and MET positivity) and cannot be removed by surgery. It is for people who have not yet received treatment for their advanced or metastatic cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.